Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91928
Title:
Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer.
Authors:
Attard-Montalto, S P; Camacho-Hübner, C; Cotterill, A M; D'Souza-Li, L; Daley, S; Bartlett, K; Halliday, D; Eden, Tim O B
Abstract:
Changes in insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding proteins (IGFBPs) were correlated with protein synthesis and breakdown using [1-13C]leucine before chemotherapy and during subsequent febrile neutropenia (FN) in eight children with cancer, aged 6.3-17.5 y. IGF-I levels were similar to age-matched controls before chemotherapy (mean +/- SEM: 250+/-28 and 228+/-22 microg l(-1), respectively). During FN, IGF-I fell to 156+/-22 microg l(-1) (p = 0.02), and rose to 276+/-27 microg l(-1) with recovery at 6 months (p = 0.004). Similarly, IGFBP-3 decreased from 4.0+/-0.2 mg l(-1) before chemotherapy to 3.0+/-0.3 mg l(-1) during FN (p = 0.01), and returned to 4.1+/-0.2 mg l(-1) at 6 months (p = 0.01). IGF-I correlated with IGFBP-3 (r = +0.7, p < 0.001). Scanning densitometry showed a decrease in IGFBP-3 from 94 to 54% during FN, when the presence of IGFBP-3 protease activity was observed. Compared with normal human serum, IGFBP-2 was elevated throughout the study. IGFBP-1 increased from 14.6+/-3.5 to 30.6+/-2.8 microg l(-1) (p = 0.004), whereas serum insulin decreased from 26.5+/-6.8 to 7.8+/-0.8 mU l(-1) (p = 0.03) before and during FN, respectively. Whilst IGF-I and IGFBP-3 fell, daytime growth hormone increased from 3.3+/-0.6 to 6.7+/-0.8 mU l(-1) (p=0.01), and cortisol from 197+/-48 to 594+/-98 nmol l(-1) (p = 0.005). Albumin decreased from 47+/-2 to 38+/-2 g l(-1) (p = 0.004) and improved to 47+/-2 g l(-1) with recovery (p = 0.003). Protein synthesis increased from 4.5+/-0.4 to 5.0+/-0.6 g kg(-1)d(-1) before chemotherapy and during FN, while protein breakdown rose from 5.4+/-0.4 to 6.3+/-0.4 kg(-1)d(-1). Increasing protein breakdown was related to falling IGF-I and IGFBP-3 levels. Modification of IGFBP-3 by circulating proteolytic activity may alter IGF bioavailability, allowing protein synthesis to increase during periods of severe catabolic stress.
Affiliation:
Department of Paediatrics, St Luke's Hospital, Gwardamangia, Malta.
Citation:
Changes in protein turnover, IGF-I and IGF binding proteins in children with cancer. 1998, 87 (1):54-60 Acta Paediatr.
Journal:
Acta Paediatrica
Issue Date:
Jan-1998
URI:
http://hdl.handle.net/10541/91928
DOI:
10.1111/j.1651-2227.1998.tb01386.x
PubMed ID:
9510448
Type:
Article
Language:
en
ISSN:
0803-5253
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAttard-Montalto, S Pen
dc.contributor.authorCamacho-Hübner, Cen
dc.contributor.authorCotterill, A Men
dc.contributor.authorD'Souza-Li, Len
dc.contributor.authorDaley, Sen
dc.contributor.authorBartlett, Ken
dc.contributor.authorHalliday, Den
dc.contributor.authorEden, Tim O Ben
dc.date.accessioned2010-02-12T12:17:57Z-
dc.date.available2010-02-12T12:17:57Z-
dc.date.issued1998-01-
dc.identifier.citationChanges in protein turnover, IGF-I and IGF binding proteins in children with cancer. 1998, 87 (1):54-60 Acta Paediatr.en
dc.identifier.issn0803-5253-
dc.identifier.pmid9510448-
dc.identifier.doi10.1111/j.1651-2227.1998.tb01386.x-
dc.identifier.urihttp://hdl.handle.net/10541/91928-
dc.description.abstractChanges in insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding proteins (IGFBPs) were correlated with protein synthesis and breakdown using [1-13C]leucine before chemotherapy and during subsequent febrile neutropenia (FN) in eight children with cancer, aged 6.3-17.5 y. IGF-I levels were similar to age-matched controls before chemotherapy (mean +/- SEM: 250+/-28 and 228+/-22 microg l(-1), respectively). During FN, IGF-I fell to 156+/-22 microg l(-1) (p = 0.02), and rose to 276+/-27 microg l(-1) with recovery at 6 months (p = 0.004). Similarly, IGFBP-3 decreased from 4.0+/-0.2 mg l(-1) before chemotherapy to 3.0+/-0.3 mg l(-1) during FN (p = 0.01), and returned to 4.1+/-0.2 mg l(-1) at 6 months (p = 0.01). IGF-I correlated with IGFBP-3 (r = +0.7, p < 0.001). Scanning densitometry showed a decrease in IGFBP-3 from 94 to 54% during FN, when the presence of IGFBP-3 protease activity was observed. Compared with normal human serum, IGFBP-2 was elevated throughout the study. IGFBP-1 increased from 14.6+/-3.5 to 30.6+/-2.8 microg l(-1) (p = 0.004), whereas serum insulin decreased from 26.5+/-6.8 to 7.8+/-0.8 mU l(-1) (p = 0.03) before and during FN, respectively. Whilst IGF-I and IGFBP-3 fell, daytime growth hormone increased from 3.3+/-0.6 to 6.7+/-0.8 mU l(-1) (p=0.01), and cortisol from 197+/-48 to 594+/-98 nmol l(-1) (p = 0.005). Albumin decreased from 47+/-2 to 38+/-2 g l(-1) (p = 0.004) and improved to 47+/-2 g l(-1) with recovery (p = 0.003). Protein synthesis increased from 4.5+/-0.4 to 5.0+/-0.6 g kg(-1)d(-1) before chemotherapy and during FN, while protein breakdown rose from 5.4+/-0.4 to 6.3+/-0.4 kg(-1)d(-1). Increasing protein breakdown was related to falling IGF-I and IGFBP-3 levels. Modification of IGFBP-3 by circulating proteolytic activity may alter IGF bioavailability, allowing protein synthesis to increase during periods of severe catabolic stress.en
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshAnthropometry-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCachexia-
dc.subject.meshChild-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInsulin-
dc.subject.meshInsulin-Like Growth Factor Binding Proteins-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMuscle Proteins-
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma-
dc.subject.meshPrognosis-
dc.subject.meshRadioimmunoassay-
dc.subject.meshReference Values-
dc.subject.meshRegression Analysis-
dc.subject.meshRhabdomyosarcoma, Alveolar-
dc.titleChanges in protein turnover, IGF-I and IGF binding proteins in children with cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Paediatrics, St Luke's Hospital, Gwardamangia, Malta.en
dc.identifier.journalActa Paediatricaen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.